Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (Nasdaq: CDNA) announced a strategic partnership with OrganX to develop clinical decision support tools for transplant patients. This collaboration aims to integrate AlloSure, a dd-cfDNA assay, with large transplant databases, providing innovative analytics for organ injury assessment. CareDx's CEO highlighted that this partnership will enhance its leadership in multi-modality testing. OrganX's founder emphasized their shared goal of improving patient quality of life through advanced digital health solutions. The collaboration presents promising benefits but also carries inherent risks, as noted in CareDx's forward-looking statements.
CareDx, a precision medicine company, announced its participation in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 8, 2021. The event will feature a management presentation scheduled for 1:40 p.m. Pacific time / 4:40 p.m. Eastern time. Investors can listen to the live webcast through CareDx’s investor relations page. CareDx specializes in high-value healthcare solutions for transplant patients and their caregivers.
CareDx, Inc. (CDNA) has initiated the Molecular Assessment and Profiling of Liver Transplant Recipients (MAPLE) Study at Mount Sinai Hospital, enrolling the first patient. This multi-center study will evaluate the LiverCare platform, which utilizes various testing methodologies including donor-derived cell-free DNA and gene expression profiling to assess liver allograft status. The study aims to enroll 1500 liver transplant recipients and underscores CareDx's commitment to advancing care in transplant medicine.
CareDx, Inc. (Nasdaq: CDNA) announced a minority investment in Miromatrix, a biotech firm focused on developing bioengineered organs to reduce the transplant waiting list. This collaboration will leverage CareDx's technology for research and development initiatives. The significant shortage of available organs impacts thousands annually, with over 40,000 kidney patients dying each year due to this crisis. Miromatrix's patented technology aims to create fully implantable organs like livers and kidneys, aligning with CareDx's mission to enhance transplant patient care.
CareDx, a precision medicine company focused on healthcare solutions for transplant patients, announced its participation in the Jefferies Virtual Healthcare Conference. The event will take place on June 1, 2021, at 10:00 a.m. PT / 1:00 p.m. ET. Investors can access the live webcast through the investor relations section of CareDx's website. CareDx specializes in testing services and digital solutions along the transplant patient journey, making it a leading provider of genomics-based information for transplant care.
CareDx Announces Innovations in Kidney Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA) will showcase advancements in donor-derived cell-free DNA (dd-cfDNA) at the 3rd Annual Global Kidney Innovations Summit on May 13-14, 2021. Reg Seeto, President and CEO, will present on May 14, discussing AlloSure, a blood test that significantly improves organ rejection detection post-transplant. The summit, organized by the American Association of Kidney Patients, aims to enhance global kidney health awareness and innovation.
CareDx reported strong first-quarter results for 2021, achieving $67.4 million in revenue, a 76% increase year-over-year. The company provided around 33,200 AlloSure and AlloMap patient results, with over 60 U.S. transplant centers adopting AlloSure Kidney protocols. A successful public offering raised approximately $188.7 million, boosting total cash and equivalents to $374.3 million. CareDx has increased its full-year revenue guidance to between $270 million and $280 million, reflecting continued growth in the transplant ecosystem.
CareDx, Inc. (Nasdaq: CDNA) announced the presentation of 15 heart abstracts at the ISHLT Annual Meeting on April 24-28, 2021. The company will showcase a total of 22 abstracts, reflecting its leadership in cardiothoracic care. Notably, a virtual symposium titled “HeartCare: The Utility of Multi-Modality in Transplant Patient Care” will occur on April 25 from 11:30 a.m. to 12:30 p.m. Eastern Time. Presented by experts, the research emphasizes innovative diagnostics for heart transplant rejection detection.
CareDx, Inc. (Nasdaq: CDNA) has announced that Medicare coverage for its transplant testing services remains unchanged under a new universal coverage policy by Palmetto MolDx. The policy reaffirms patient access to services essential for managing organ transplant care. CareDx’s AlloMap and AlloSure tests, which are critical for identifying organ rejection, have been validated through rigorous studies. This continued coverage supports CareDx's mission in enhancing patient care and solidifies its role as a leader in precision medicine.
CareDx (Nasdaq: CDNA) announced its participation in the upcoming International Society of Heart and Lung Transplantation Annual Meeting from April 24-28, 2021, where it will present 22 clinical abstracts, focusing on its AlloSure Lung surveillance technology for lung transplant patients. This technology, expanding on previous successes in heart and kidney transplants, utilizes donor-derived cell-free DNA to non-invasively assess allograft injury. Notably, seven abstracts will detail its clinical utility in lung transplantation, highlighting significant ongoing research.